Unlike inclisiran’s siRNA mechanism, VERVE-101 uses an mRNA-encoded adenine base editor plus a guide RNA that specifically targets the PCSK9 gene. Base editing alters a single base pair in the ...
If those predictions are correct, AZ’s oral PCSK9 could have to contend with cut-price antibody drugs, a long-acting siRNA benefiting from marketing alongside Novartis’ blockbuster heart ...
AstraZeneca's take on the PCSK9 inhibitor – an antisense drug ... competition – notably Novartis' small interfering RNA (siRNA) therapy Leqvio (inclisiran), which only needs to be administered ...
PCSK9, which mediates post-translational destruction of LDL receptors, is raised in HoFH and is further raised by statins. LDL-C, following apheresis, quickly rebounds due to increased synthesis ...